CM
BMRN icon

Caption Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Caption Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.8M Buy
+209,500
New +$12.2M 0.07% 292
2025
Q3 		– Sell
-12,000
Closed -$660K – 1681
2025
Q2 		$660K Sell
12,000
-31,500
-72% -$1.85M 0.01% 1044
2025
Q1 		$3.08M Buy
43,500
+13,500
+45% +$908K 0.03% 540
2024
Q4 		$1.97M Sell
30,000
-12,500
-29% -$837K 0.02% 696
2024
Q3 		$2.99M Hold
42,500
– – 0.05% 444
2024
Q2 		$3.5M Sell
42,500
-15,000
-26% -$1.25M 0.05% 363
2024
Q1 		$5.02M Buy
57,500
+5,500
+11% +$492K 0.08% 296
2023
Q4 		$5.01M Buy
52,000
+12,600
+32% +$1.11M 0.07% 339
2023
Q3 		$3.49M Sell
39,400
-320,900
-89% -$28.6M 0.05% 424
2023
Q2 		$31.2M Buy
360,300
+280,900
+354% +$26.4M 0.55% 24
2023
Q1 		$7.72M Sell
79,400
-98,600
-55% -$10.2M 0.15% 159
2022
Q4 		$18.4M Buy
178,000
+78,000
+78% +$7.32M 0.29% 77
2022
Q3 		$8.48M Sell
100,000
-6,300
-6% -$561K 0.12% 205
2022
Q2 		$8.81M Buy
106,300
+18,800
+21% +$1.5M 0.12% 215
2022
Q1 		$6.74M Buy
87,500
+45,000
+106% +$3.77M 0.08% 331
2021
Q4 		$3.75M Buy
+42,500
New +$3.51M 0.04% 551
2021
Q2 		– Sell
-121,400
Closed -$9.17M – 1309
2021
Q1 		$9.17M Sell
121,400
-203,000
-63% -$16.6M 0.2% 127
2020
Q4 		$28.4M Buy
324,400
+144,400
+80% +$11.4M 0.65% 22
2020
Q3 		$13.7M Buy
180,000
+115,000
+177% +$11.6M 0.32% 65
2020
Q2 		$8.02M Buy
65,000
+35,000
+117% +$3.48M 0.27% 93
2020
Q1 		$2.53M Sell
30,000
-311,500
-91% -$26.8M 0.14% 197
2019
Q4 		$28.9M Buy
+341,500
New +$25.8M 0.97% 10
2019
Q3 		– Sell
-37,300
Closed -$3.19M – 715
2019
Q2 		$3.19M Buy
37,300
+23,800
+176% +$2.04M 0.16% 183
2019
Q1 		$1.2M Buy
+13,500
New +$1.25M 0.07% 315
2018
Q1 		– Sell
-40,000
Closed -$3.57M – 227
2017
Q4 		$3.57M Buy
+40,000
New +$3.48M 0.37% 82

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caption Management's BMRN Position: Q1 2026 in Review

Caption Management increased its BioMarin Pharmaceuticals (BMRN) stake by 184% in Q1 2026, buying an estimated $2.09M and bringing the position to 55,300 shares worth $3.12M. The position accounts for 0.02% of the portfolio, ranked #682.

Caption Management first reported a position in BMRN in Q4 2017 and has held it in 17 quarters since. The position peaked at $9.87M in Q2 2023. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • Caption Management held 55,300 shares of BioMarin Pharmaceuticals worth $3.12M as of Q1 2026.
  • Caption Management bought 35,800 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $2.09M.
  • BioMarin Pharmaceuticals made up 0.02% of Caption Management's portfolio in Q1 2026, its #682 holding.
  • Caption Management first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 17 quarters since.
  • Caption Management's BioMarin Pharmaceuticals position peaked at $9.87M in Q2 2023.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.